Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Fuji
Moodys
Medtronic
Baxter
US Army
US Department of Justice
Cerilliant
Johnson and Johnson
Harvard Business School

Generated: August 21, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Low dose estrogen interrupted hormone replacement therapy
Abstract:A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17.beta.-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17.beta.-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 .mu.g per day of norgestimate.
Inventor(s): Casper; Robert F. (Toronto, CA), Shangold; Gary A. (Califon, NJ), Ausmanas; Militza K. (Lake Forest, IL)
Assignee: Duramed Pharmaceutials, Inc. (Cincinnati, OH) Jencap Research Ltd. (Toronto, Ontario, CA)
Application Number:11/439,171
Patent Claims: 1. A method of treating a female in need of hormone replacement therapy, the method comprising administering: (a) three consecutive daily dosage forms or an equivalent thereof comprising a substance exhibiting estrogenic activity; followed by (b) three consecutive daily dosage forms or an equivalent thereof comprising a substance exhibiting estrogenic activity and a substance exhibiting progestogenic activity equivalent to about 90 .mu.g norgestimate per day.

2. The method of claim 1, wherein the method further comprises administering a placebo, an iron supplement, a vitamin supplement, or a combination thereof.

3. The method of claim 1, wherein the dosage forms are administered orally, parenterally, transdermally, transmucosally, intramuscularly, or intravaginally.

4. The method of claim 3, wherein the dosage forms are in oral form.

5. The method of claim 4, wherein the oral dosage form is a tablet.

6. A pharmaceutical kit comprising: (a) three consecutive daily dosage forms or an equivalent thereof comprising a substance exhibiting estrogenic activity; and (b) three consecutive daily dosage forms or an equivalent thereof comprising a substance exhibiting estrogenic activity and a substance exhibiting progestogenic activity equivalent to about 90 .mu.g norgestimate per day; wherein the dosage forms of (a) and (b) are positioned sequentially in the kit.

7. The kit of claim 6, wherein the kit further comprises administering a placebo, an iron supplement, a vitamin supplement, or a combination thereof.

8. The kit of claim 6, wherein the dosage forms are administered orally, parenterally, transdermally, transmucosally, intramuscularly, or intravaginally.

9. The kit of claim 8, wherein the dosage forms are in oral form.

10. The kit of claim 9, wherein the oral dosage form is a tablet.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Medtronic
Citi
Merck
Julphar
McKinsey
Farmers Insurance
Fuji
Argus Health
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot